Cargando...
Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis
BACKGROUND & AIMS: The most prescribed non-nucleoside reverse transcriptase inhibitor efavirenz has been associated with elevated risk for dyslipidemia and hepatic steatosis in HIV-infected patients but the underlying mechanisms remain elusive. Here we investigated the role of pregnane X recepto...
Gardado en:
| Publicado en: | J Hepatol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6462244/ https://ncbi.nlm.nih.gov/pubmed/30677459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2018.12.038 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|